D. Heim

发表

Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model.

J. Tisdale, Y. Hanazono, C. Dunbar, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency

D. Heim, Cynthia E. Cynthia, 2000, Immunological reviews.

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07)

M. Gregor, J. Passweg, T. Pabst, 2014, Leukemia & lymphoma.

Prospective change control analysis of transfer of platelet concentrate production from a specialized stem cell transplantation unit to a blood transfusion center

A. Gratwohl, A. Buser, D. Heim, 2012, Journal of clinical apheresis.

GUIDELINES FOR THE TRANSFUSION OF PLATELETS

M. Toungouz, D. Heim, A. Ferrant, 2007, Acta clinica Belgica.

Impact of HLA-DPB1 haplotypes on outcome of 10/10 matched unrelated hematopoietic stem cell donor transplants depends on MHC-linked microsatellite polymorphisms.

A. Gratwohl, H. Baldomero, J. Passweg, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study

H. Baldomero, J. Passweg, D. Heim, 2022, Bone Marrow Transplantation.

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

E. Vellenga, M. Jongen‐Lavrencic, L. Michaux, 2020, Leukemia.

Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV

Martin C. Müller, H. Einsele, K. Spiekermann, 2010 .

Biological markers of hemostasis and endothelial activation in patients with a hematological malignancy with or without stem cell transplants

J. Passweg, D. Heim, B. Drexler, 2019, European journal of haematology.

Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease.

A. Gratwohl, A. Buser, A. Tichelli, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Angiogenesis and vascular endothelial growth factor‐/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2‐V617F mutational status

A. Gratwohl, A. Buser, A. Tichelli, 2009, British journal of haematology.

Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

C. Lengerke, J. Passweg, A. Tzankov, 2018, Annals of Hematology.

Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis

J. Passweg, A. Widmer, M. Weisser, 2014, BMC Infectious Diseases.

High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation

M. Ghielmini, A. Gratwohl, A. Buser, 2007, Bone Marrow Transplantation.

Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient

S. Krähenbühl, A. Gratwohl, J. Diebold, 2010, Acta oncologica.

Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.

M. Gregor, D. Betticher, T. Pabst, 2010, Swiss medical weekly.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Martin C. Müller, N. Schmitz, J. Hasford, 2015, Blood.

G-CSF for Imatinib-induced neutropenia

A. Gratwohl, A. Tichelli, D. Heim, 2003, Leukemia.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Role of allogeneic transplantation in chronic myeloid leukemia

A. Gratwohl, D. Heim, 2008, Expert review of hematology.

Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections

F. Ruschitzka, C. Seiler, C. Lovis, 2016, BMC Infectious Diseases.

New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation

J. Passweg, A. Tichelli, D. Heim, 2020, In Vivo.

CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL

M. Vigolo, J. Passweg, A. Tzankov, 2022, EJHaem.

Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation

M. Battegay, A. Gratwohl, A. Widmer, 2010, Bone Marrow Transplantation.

Pre‐transplant donor‐specific HLA antibodies and risk for poor first‐year renal transplant outcomes: results from the Swiss Transplant Cohort Study

F. Ruschitzka, C. Lovis, S. De Geest, 2021, Transplant international : official journal of the European Society for Organ Transplantation.

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

D. Betticher, T. Pabst, M. Bargetzi, 2019, Swiss medical weekly.

High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparities

H. Baldomero, J. Passweg, D. Heim, 2015, Bone Marrow Transplantation.

Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study

M. Ghielmini, D. Rossi, H. Baldomero, 2018, Bone Marrow Transplantation.

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantati

H. Einsele, G. Mufti, A. Hunter, 2006, Blood.

Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.

J. Passweg, D. Heim, M. Stern, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors.

Y. Hanazono, C. Dunbar, R. Donahue, 1999, Blood.

High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease

C. Lengerke, J. Passweg, A. Tzankov, 2018, Bone Marrow Transplantation.

Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality

A. Gratwohl, A. Buser, J. Passweg, 2009, European journal of haematology.

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Martin C. Müller, H. Einsele, J. Hasford, 2018, Leukemia.

Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex.

A. Gratwohl, A. Tichelli, D. Heim, 2009, Blood.

Inability to work and need for disability pension among long-term survivors of hematopoietic stem cell transplantation

A. Buser, J. Passweg, A. Tichelli, 2017, Bone Marrow Transplantation.

Cytopenia and hematopoietic recovery after low intensity conditioning transplants.

A. Gratwohl, A. Buser, J. Passweg, 2004, Croatian medical journal.

Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)

T. Pabst, E. Zucca, M. Bargetzi, 2013, Leukemia & lymphoma.

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

N. Kröger, S. Iacobelli, R. Brand, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

H. Einsele, M. Egger, C. Schmoor, 2009, The Lancet. Oncology.

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

E. Vellenga, M. Jongen‐Lavrencic, M. Vekemans, 2021, Cancers.

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

M. Jongen‐Lavrencic, M. Gregor, G. Ossenkoppele, 2022, Leukemia.

Current role of stem cell transplantation in chronic myeloid leukaemia.

A. Gratwohl, D. Heim, 2009, Best practice & research. Clinical haematology.

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial

T. Buclin, L. Decosterd, M. Gregor, 2014, Cancer Chemotherapy and Pharmacology.

High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma

A. Gratwohl, A. Buser, J. Passweg, 2004, Bone Marrow Transplantation.

Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation

D. Heim, S. Gerull, M. Medinger, 2015, Annals of Hematology.

Secondary Malignancies in CML Patients – Data From the German CML Study IV

Martin C. Müller, H. Einsele, J. Hasford, 2012 .

Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02)

M. Gregor, M. Bargetzi, D. Heim, 2010, Leukemia & lymphoma.

Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents.

C. Lengerke, A. Buser, J. Passweg, 2016, Cancer genomics & proteomics.

Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma.

J. Passweg, A. Tichelli, C. Kalberer, 2020, Cytotherapy.

Central venous catheter-associated bloodstream infection and colonisation of insertion site and catheter tip. What are the rates and risk factors in haematology patients?

C. Schmoor, A. Widmer, D. Heim, 2010, Annals of Hematology.

colonisation of insertion-site and catheter tip. What are the rates and risk

C. Schmoor, A. Widmer, D. Heim, 2010 .

Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study.

D. Heim, G. Mertes, G. Mahla, 1999, Diabetes, nutrition & metabolism.

First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study

F. Ruschitzka, C. Seiler, C. Lovis, 2020, American Journal of Transplantation.

Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature.

A. Gratwohl, A. Widmer, M. Weisser, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Candida krusei– a serious complication in patients with hematological malignancies: successful treatment with caspofungin

M. Battegay, A. Gratwohl, M. Weisser, 2008, Transplant infectious disease : an official journal of the Transplantation Society.

The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable

A. Gratwohl, J. Passweg, D. Heim, 2007, Bone Marrow Transplantation.

Quantitative immunophenotypic characterization, cryopreservation, and enrichment of second- and third-trimester human fetal cord blood hematopoietic stem cells (progenitor cells).

W. Holzgreve, D. Heim, D. Surbek, 1998, American journal of obstetrics and gynecology.

Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants

A. Gratwohl, A. Buser, J. Passweg, 2005, Bone Marrow Transplantation.

Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy.

J. Passweg, A. Tichelli, M. Weisser, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment

A. Gratwohl, A. Buser, J. Passweg, 2007, Bone Marrow Transplantation.

Role of primacy of birth in HLA-identical sibling transplantation.

A. Gratwohl, A. Buser, J. Passweg, 2007, Blood.

High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation

A. Sanchez‐Mazas, H. Baldomero, J. Passweg, 2019, Bone Marrow Transplantation.

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial

J. Passweg, M. Ansari, D. Heim, 2020, Annals of Hematology.

Burden and Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss Transplant Cohort Study

F. Ruschitzka, C. Seiler, C. Lovis, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Large granular lymphocyte expansion after allogeneic hematopoietic stem cell transplant is associated with a cytomegalovirus reactivation and shows an indolent outcome.

A. Gratwohl, A. Buser, A. Tichelli, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dasatinib for treatment of CAR T-cell therapy-related complications

J. Passweg, K. Baur, D. Heim, 2022, Journal for ImmunoTherapy of Cancer.

Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation

A. Gratwohl, A. Tichelli, D. Heim, 2004, Leukemia.

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation

J. Passweg, K. Rentsch, D. Heim, 2022, Bone Marrow Transplantation.

Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study

H. Baldomero, J. Passweg, D. Heim, 2019, Annals of Hematology.

Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT

A. Gratwohl, A. Buser, J. Passweg, 2011, Bone Marrow Transplantation.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

R. Larson, G. Rosti, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Martin C. Müller, H. Heimpel, H. Einsele, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD.

W. Holzgreve, A. Gratwohl, J. Passweg, 2006, Blood.

Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor

A. Gratwohl, A. Tichelli, D. Heim, 2011, Haematologica.

Complete remission of alopecia universalis after allogeneic hematopoietic stem cell transplantation.

A. Gratwohl, J. Passweg, A. Tichelli, 2005, Blood.

Skin disinfection with octenidine dihydrochloride for central venous catheter site care: a double-blind, randomized, controlled trial.

C. Schmoor, A. Gratwohl, A. Widmer, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

T. Brümmendorf, K. Spiekermann, M. Pfreundschuh, 2017, Leukemia.

Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner.

A. Buser, J. Passweg, A. Tichelli, 2012, Swiss medical weekly.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

J. Hasford, T. Brümmendorf, D. Hossfeld, 2016, Leukemia.

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

H. Dombret, S. Chevret, P. Chevallier, 2016, The New England journal of medicine.

Pretransplant HLA mistyping in diagnostic samples of acute myeloid leukemia patients due to acquired uniparental disomy

A. Tichelli, J. Delaunay, D. Heim, 2012, Leukemia.

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

R. Larson, M. Baccarani, J. Lipton, 2007, Blood.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

J. Hasford, T. Brümmendorf, K. Spiekermann, 2018, Haematologica.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Martin C. Müller, H. Einsele, J. Hasford, 2014, Annals of Hematology.

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

Martin C. Müller, J. Hasford, K. Spiekermann, 2013, Annals of Hematology.

Double allogeneic hematopoietic SCT as a rescue therapy for poor-risk hematological malignancies

A. Gratwohl, A. Buser, J. Passweg, 2010, Bone Marrow Transplantation.

The value of the post‐thaw CD34+ count with and without DMSO removal in the setting of autologous stem cell transplantation

A. Buser, J. Passweg, D. Heim, 2019, Transfusion.

Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation – A Single Centre Study

C. Lengerke, J. Passweg, D. Heim, 2020, AntiCancer Research.

Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure

J. Passweg, D. Heim, M. Medinger, 2017, Annals of Hematology.

Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation.

A. Gratwohl, J. Passweg, A. Tichelli, 2007, Blood.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

H. Einsele, M. Egger, C. Schmoor, 2011, Blood.

Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation.

A. Gratwohl, J. Passweg, A. Tichelli, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.

C. Schmoor, D. Heim, G. Socié, 2017, The Lancet. Haematology.

Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation

C. Lengerke, J. Passweg, M. Weisser, 2015, Bone Marrow Transplantation.

Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation

A. Buser, J. Passweg, A. Tichelli, 2020, Annals of Hematology.

Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation.

A. Buser, J. Passweg, T. Volken, 2021, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation.

H. Baldomero, J. Passweg, S. Buhler, 2021, Blood advances.

Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin

J. Passweg, D. Heim, M. Medinger, 2022, Bone Marrow Transplantation.

High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation

A. Gratwohl, M. Gregor, A. Tichelli, 2002, Bone Marrow Transplantation.

Aplastic anemia and concomitant autoimmune diseases

A. Gratwohl, A. Buser, J. Passweg, 2009, Annals of Hematology.

Kinetics of peripheral blood chimerism for surveillance of patients with leukemia and chronic myeloid malignancies after reduced-intensity conditioning allogeneic hematopoietic SCT

H. Baldomero, J. Passweg, A. Tichelli, 2015, Bone Marrow Transplantation.

Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

J. Passweg, A. Tichelli, D. Heim, 2017, Leukemia research.

Oral health risks associated with HLA‐types of patients undergoing hematopoietic stem cell transplantation

A. Gratwohl, J. Passweg, A. Tichelli, 2007, European journal of haematology.

Clinical‐grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation

J. Passweg, A. Tichelli, C. Kalberer, 2009, Transfusion.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.

H. Einsele, C. Schmoor, A. Zander, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

stem-cell transplantation Premature cardiovascular disease after allogeneic hematopoietic

A. Gratwohl, D. Heim, C. Bucher, 2013 .

Are there risk factors for snowboard injuries? A case-control multicentre study of 559 snowboarders

Aristomenis K Exadaktylos, Heinz Zimmermann, A. Exadaktylos, 2010, British Journal of Sports Medicine.

Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.

A. Buser, J. Passweg, D. Heim, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lung Histology Predicts Outcome of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplantation

L. Bubendorf, J. Passweg, A. Tichelli, 2013, Biology of Blood and Marrow Transplantation.

Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study

H. Dombret, S. Chevret, P. Chevallier, 2015 .

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort

E. Haralambieva, R. Grobholz, C. B. Rudolf, 2021, Annals of Hematology.

Baseline calprotectin fails to predict incidence of acute gastrointestinal graft vs. host disease: a prospective study

A. Buser, J. Passweg, D. Heim, 2018, Bone Marrow Transplantation.

Forty years of haematopoietic stem cell transplantation: a review of the Basel experience.

A. Gratwohl, A. Buser, J. Passweg, 2014, Swiss medical weekly.

Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT

A. Gratwohl, A. Buser, A. Tichelli, 2011, Bone Marrow Transplantation.

Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series

J. Passweg, D. Heim, M. Recher, 2022, AntiCancer Research.

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

D. Betticher, T. Pabst, M. Bargetzi, 2015, Swiss medical weekly.

Aplastic anemia in association with a lymphoproliferative neoplasm: coincidence or causality?

A. Buser, J. Passweg, A. Tichelli, 2012, Leukemia research.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party

N. Kröger, I. Yakoub-Agha, E. Tholouli, 2016, Bone Marrow Transplantation.

Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best percepted in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies

C. Lengerke, J. Passweg, A. Tzankov, 2020, Bone Marrow Transplantation.

External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study

Jan A. Roth, H. Baldomero, J. Passweg, 2022, HemaSphere.

Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016.

H. Baldomero, J. Passweg, T. Pabst, 2018, Swiss medical weekly.

Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood

A. Gratwohl, J. Passweg, A. Tichelli, 2010, International journal of laboratory hematology.

No evidence of plasticity in hair follicles of recipients after allogeneic hematopoietic stem cell transplantation.

A. Gratwohl, J. Passweg, A. Tichelli, 2005, Experimental hematology.

transplantation, and apparently absence of chronic GvHD stem cell transplantation is associated with age, time interval since Spermatogenesis in long-term survivors after allogeneic hematopoietic

A. Gratwohl, J. Passweg, A. Tichelli, 2013 .

Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)

A. Tobler, M. Bargetzi, D. Heim, 2009, Leukemia & lymphoma.

Clinical prediction model for prognosis in kidney transplant recipients (KIDMO): study protocol

F. Ruschitzka, N. Mueller, T. Fehr, 2023, Diagnostic and Prognostic Research.

Physical and not mental health is impaired in very long-term survivors after HSCT compared with their respective donors: a paired analysis.

A. Gratwohl, A. Buser, A. Tichelli, 2008, Blood.

Rapid adaptation drives invasion of airway donor microbiota by Pseudomonas after lung transplantation

A. Buckling, L. Farinelli, F. Ruschitzka, 2017, Scientific Reports.

Lung resection in hematologic patients with pulmonary invasive fungal disease.

L. Bubendorf, M. Battegay, A. Gratwohl, 2012, Chest.

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

G. Martinelli, F. Giles, J. Duyster, 2013, Leukemia research.

Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies

A. Gratwohl, J. Duyster, A. Gianella-Borradori, 2008 .

Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV,

Martin C. Müller, H. Einsele, K. Spiekermann, 2011 .

Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.

C. Lengerke, A. Buser, J. Passweg, 2016, Leukemia research.

Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

Martin C. Müller, H. Heimpel, H. Einsele, 2012 .

Patient and product factors affecting platelet transfusion results

A. Gratwohl, M. Gregor, A. Buser, 2008, Transfusion.

Combination therapy for multidrug‐resistant cytomegalovirus disease

M. Battegay, J. Passweg, C. Kalberer, 2015, Transplant infectious disease : an official journal of the Transplantation Society.

Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy.

J. Passweg, E. Holler, U. Holtick, 2022, Transplantation and cellular therapy.

[Diagnosis and Therapy of Acute Myeloid Leukemia].

C. Lengerke, J. Passweg, D. Heim, 2019, Therapeutische Umschau. Revue therapeutique.

[Acute lymphoblastic leukemia - diagnosis and therapy].

C. Lengerke, J. Passweg, D. Heim, 2019, Therapeutische Umschau. Revue therapeutique.

High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML

A. Gratwohl, A. Tichelli, T. Pabst, 2011, Bone Marrow Transplantation.

Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia

A. Gratwohl, J. Passweg, A. Tichelli, 2006, Leukemia.

Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy

J. Passweg, D. Heim, M. Medinger, 2019, International journal of laboratory hematology.

The MELD upgrade exception: a successful strategy to optimize access to liver transplantation for patients with high waiting list mortality.

Brian J. Lang, F. Ruschitzka, C. Lovis, 2021, HPB : the official journal of the International Hepato Pancreato Biliary Association.

P834: REAL-WORLD EVIDENCE OF SAFETY AND EFFECTIVENESS OF ECULIZUMAB AND SWITCH TO RAVULIZUMAB IN A SWISS PATIENT POPULATION WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

D. Heim, A. Rovó, N. Cantoni, 2022, HemaSphere.

Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV

Martin C. Müller, H. Heimpel, S. Schnittger, 2010 .

CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas

A. Buser, J. Passweg, T. Volken, 2023, Bone Marrow Transplantation.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

R. Larson, G. Rosti, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Martin C. Müller, N. Schmitz, J. Hasford, 2015, Blood.

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

H. Dombret, S. Chevret, P. Chevallier, 2016, The New England journal of medicine.

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan

J. Passweg, M. Ansari, D. Heim, 2023, Bone Marrow Transplantation.

Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV

Martin C. Müller, H. Einsele, M. Pfreundschuh, 2011 .

Role of allogeneic transplantation in chronic myeloid leukemia

A. Gratwohl, D. Heim, 2008, Expert review of hematology.

Lack of association of travel time to transplant center and posttransplant care model with outcome parameters after allogeneic transplantation

J. Passweg, T. Pabst, D. Heim, 2021, Bone Marrow Transplantation.

A. Gratwohl, A. Buser, J. Passweg, 2009, European journal of haematology.